

Press release from Emotra AB (publ)
Göteborg, December 19, 2013

Emotra decides to carry out a rights issue, on condition of shareholder approval

Yesterday, on December 18, 2013, the board of directors of Emotra AB (publ) decided, on condition of the resolution being approved at an extraordinary shareholder meeting, on a rights issue amounting to 648,945 new shares, or 9.7 MSEK. Emotra has received subscription commitments for 3,005,000 SEK, as well as a letter of intent covering a further 1,183,180 SEK, which altogether corresponds to approximately 43% of the total share issue volume. This new share issue is also open to the general public.

Primary Objective of New Share Issue

Emotra's primary goal with this rights issue is to finance the preparation and international launch of the company's method, EDOR. More precisely, this share issue is mainly intended to finance Emotra's investment in forging strong alliances with Europe's leading clinics. Emotra will collaborate with these clinics in carrying out multi-centre studies as well as several research projects that have the potential to radically change the way risk patients' suicide risks are diagnosed in the psychiatric realm.

Summary of the Share Offering

- Record day: January 10, 2014.
- Subscription period: January 16–30, 2014.
- Subscription price: 15.00 SEK.
- Preferential right: Each outstanding share entitles the owner to one (1) subscription right. Three (3) subscription rights allow the purchase of one (1) new share.
- Number of shares in this issue: The offering comprises 648,945 new shares.
- Issue volume: Approximately 9.7 MSEK.
- Trading in subscription rights: Trading in subscription rights will be carried out on AktieTorget during the period January 16 – 27, 2014.
- Trading in PSS: Trading in PSS (Paid Subscribed Shares) will be carried out on AktieTorget from January 16, 2014 until the share issue has been registered at Bolagsverket. We expect this registration to be completed at the end of February 2014.
- Number of shares outstanding before the new issue: 1,946,835 shares.
- Value: Appr. 29.2 MSEK (pre-money).
- Regular lot size: One (1) share.
- Subscriptions and letter of intent: Emotra has received subscription commitments for 3,005,000 SEK, as well as a letter of intent covering a further 1,183,180 SEK, which altogether corresponds to approximately 43% of the total share issue volume.

Complete terms and instructions, further information about subscription commitments as well as a memorandum and folder will be published on the company's web site (www.emotra.se), Sedermera Fondkommission's web site (www.sedermera.se) and AktieTorget's web site (www.aktietorget.se) no later than the commencement of the subscription period.

Financial Advisor

Emotra's Financial Advisor in connection with this new share issue is Sedermera Fondkommission.

For further information, please contact:

Claes Holmberg, CEO

Telephone: +46-(0)708-25 45 47

E-mail: claes@emotra.se

Lars-Håkan Thorell, Head of Research

Telephone: +46-(0)733-95 31 20

E-mail: lars@emotra.se

***Emotra AB (publ)** has developed a method – EDOR – of detecting depressed patients who are at risk of committing suicide. In studies encompassing more than 1,000 patients, this method has shown a reliability of approximately 97%. In other words, Emotra's method can determine, with 97% certainty, if a person runs a significantly higher risk of suicide attempt, facilitating decisions about where special suicide prevention measures are needed. EDOR helps the right patients get the care they need.*

Emotra AB (publ), Göteborgsvägen 74, SE-433 63 Sävedalen, Sweden

Tel: +46 708 25 45 47, www.emotra.se